Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Puma Biotechnology Inc
PBYI
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$10.20
-0.01
-0.1%
Dern. MÀJ: Oct 19, 4:40 PM
$10.20
-0.01
-0.1%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Puma Biotechnology Financials
Puma Biotechnology (PBYI) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Puma Biotechnology Sees Q3 Sales $56.000M-$59.000M vs $60.500M Est
Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $56.000 million-$59.000 million vs $60.500 million analyst estimate.
Benzinga Newsdesk
PRO
Puma Biotechnology Raises FY2026 Sales Guidance from $222.000M-$229.000M to $224.000M-$231.000M vs $222.000M Est
Puma Biotechnology (NASDAQ:PBYI) raises FY2026 sales outlook from $222.000 million-$229.000 million to $224.000 million-$231.000 million vs $222.000 million estimate.
Benzinga Newsdesk
PRO
Puma Biotechnology Q2 Adj. EPS $0.19 Beats $0.04 Estimate, Sales $53.600M Beat $53.000M Estimate
Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.04 by 375 percent. This is a 26.67 percent increase over earnings of $0.15 per share from
Benzinga Newsdesk
PRO
Puma Biotechnology Sees Q2 Sales $52.000M-$55.000M vs $52.000M Est
Second Quarter and Full Year 2026 Financial Outlook Second Quarter2026NewFull Year 2026PriorFull Year 2026Net Product Revenue$50–$52 million$202-206 million$194–$198 millionRoyalty Revenue$2–$3 million$20–$23
Benzinga Newsdesk
PRO
Puma Biotechnology Raises FY2026 Sales Guidance from $214.000M-$221.000M to $222.000M-$229.000M vs $218.000M Est
Second Quarter and Full Year 2026 Financial Outlook Second Quarter2026NewFull Year 2026PriorFull Year 2026Net Product Revenue$50–$52 million$202-206 million$194–$198 millionRoyalty Revenue$2–$3 million$20–$23
Benzinga Newsdesk
PRO
Puma Biotechnology Q1 Adj. EPS $(0.04) Beats $(0.13) Estimate, Sales $44.800M Beat $42.000M Estimate
Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.13) by 69.23 percent. This is a 140 percent decrease over earnings of $0.10 per share from
Benzinga Newsdesk
